Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population

verfasst von: Li-Qiang Zhi, Wei Ma, Hong Zhang, Si-Xiang Zeng, Bo Chen

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Despite the knowledge on many genetic variants present in osteosarcoma, the complexity of this disease precludes placing its biology into a simple conceptual framework. RECQL is a DNA helicase involved in DNA mismatch repair and has been reported to be associated with many human cancers. We aimed to investigate the association of RECQL genetic polymorphism with osteosarcoma in a Chinese population. We selected three polymorphisms of the RECQL5 gene (rs820196, rs820200, and rs4789223) in the present study. TaqMan method was utilized for genotyping these three SNPs in 212 patients with osteosarcoma and 240 age- and sex-matched noncancer controls. In our study, we found that CC genotype in rs820196 (17.5 vs 8.3 %, P = 0.005) and AA genotype in rs4789223 (21.7 vs 14.2, P < 0.001) were more frequent in osteosarcoma group compared to the control group, respectively. We also found that the C allele of rs820196 (OR = 1.492, 95 % CI 1.138∼1.951; P = 0.004) and A allele of rs4789223 (OR = 1.767, 95 % CI: 1.354 ∼ 2.301; P < 0.001) were common in the osteosarcoma patients than those in the control subjects, respectively. Haplotype analysis showed that TTA (OR = 3.469, 95 % CI 1.798∼6.695; P < 0.001) was associated with increased risk for osteosarcoma. However, the TTG (OR = 0.578, 95 % CI 0.442∼0.756) was associated with decreased risk for osteosarcoma. Our results suggested that RECQL5 genetic polymorphisms were associated with osteosarcoma in a Chinese population.
Literatur
2.
Zurück zum Zitat Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28:86–101.PubMedCrossRef Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28:86–101.PubMedCrossRef
4.
Zurück zum Zitat Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed
5.
Zurück zum Zitat Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef
6.
Zurück zum Zitat Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer. 2013. doi:10.1002/pbc.24790. Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer. 2013. doi:10.​1002/​pbc.​24790.
7.
Zurück zum Zitat Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol. 2013. doi:10.1007/s13277-013-1227-8 Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1227-8
10.
Zurück zum Zitat He J, Wang J, Wang D, Dai S, Yv T, Chen P, Ma R, Diao C, Lv G (2013) Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocr J. (in press). He J, Wang J, Wang D, Dai S, Yv T, Chen P, Ma R, Diao C, Lv G (2013) Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocr J. (in press).
11.
Zurück zum Zitat Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics. 2010;20:507–15.PubMedCrossRef Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics. 2010;20:507–15.PubMedCrossRef
12.
Zurück zum Zitat Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.PubMedCrossRef Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.PubMedCrossRef
13.
Zurück zum Zitat Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.PubMedCrossRef Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.PubMedCrossRef
14.
15.
Zurück zum Zitat Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6:e26091.PubMedCentralPubMedCrossRef Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6:e26091.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120–2.PubMedCrossRef Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120–2.PubMedCrossRef
17.
Zurück zum Zitat Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef
18.
Zurück zum Zitat O’Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet. 2006;7:45–54.PubMedCrossRef O’Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet. 2006;7:45–54.PubMedCrossRef
19.
Zurück zum Zitat Sharma S, Doherty KM, Brosh RM. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J. 2006;398:319–37.PubMedCentralPubMedCrossRef Sharma S, Doherty KM, Brosh RM. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J. 2006;398:319–37.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Hu Y, Raynard S, Sehorn MG, Lu X, Bussen W, Zheng L, et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 2007;21:3073–84.PubMedCentralPubMedCrossRef Hu Y, Raynard S, Sehorn MG, Lu X, Bussen W, Zheng L, et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 2007;21:3073–84.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Raynard S, Bussen W, Sung P. A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. J Biol Chem. 2006;281:13861–4.PubMedCrossRef Raynard S, Bussen W, Sung P. A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. J Biol Chem. 2006;281:13861–4.PubMedCrossRef
24.
Zurück zum Zitat Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.PubMedCrossRef Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.PubMedCrossRef
26.
Zurück zum Zitat Pellatt AJ, Wolff RK, Lundgreen A, Cawthon R, Slattery ML. Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study. Int J Mol Epidemiol Genet. 2012;3:184–94.PubMedCentralPubMed Pellatt AJ, Wolff RK, Lundgreen A, Cawthon R, Slattery ML. Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study. Int J Mol Epidemiol Genet. 2012;3:184–94.PubMedCentralPubMed
Metadaten
Titel
Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population
verfasst von
Li-Qiang Zhi
Wei Ma
Hong Zhang
Si-Xiang Zeng
Bo Chen
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1425-4

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.